Recent Advances in the Discovery of Deubiquitinating Enzyme Inhibitors
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
This review examines the small molecules described over the past decade as inhibitors of any of the approximately 100 human deubiquitinating enzymes (DUBs). Structures from patent publications as well as from the primary literature are included. Inhibitors of two viral DUBs are also described since these proteases share structural similarity with one of the human DUB sub-families. The structure, function and disease associations of certain DUBs are presented. The evolution of the screening assays used to identify and characterise new inhibitors is discussed. Several emerging trends in the series are highlighted and the ‘drug-likeness’ of the various inhibitors is analysed. Large pharmaceutical company collaborations have drawn attention to this field, and these recent advances are discussed in the context of the wider range of therapeutically important DUB targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Komander, D., & Rape, M. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060310-170328 · Cited by 3,679 · cited 1×
“DUB-mediated removal of ubiquitin saves tagged proteins from being degraded, but DUBs are also involved in more subtle editing of the polyubiquitin signal [5], and are necessary to cleave ubiquitin precursors and to recycle ubiquitin monomers [6].”
A genomic and functional inventory of deubiquitinating enzymes.
Nijman, S. M. B., Luna-Vargas, M. P. A., Velds, A., Brummelkamp, T. R., Dirac, A. M. G., Sixma, T. K., & Bernards, R. (2005) · Cell · doi:10.1016/j.cell.2005.11.007 · Cited by 1,854
Cover Picture: Recoding the Genetic Code with Selenocysteine (Angew. Chem. Int. Ed. 1/2014)
Bröcker, M. J., Ho, J. M. L., Church, G. M., Söll, D., & O'Donoghue, P. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201310509 · Cited by 911
The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy
Bingol, B., Tea, J. S., Phu, L., Reichelt, M., Bakalarski, C. E., Song, Q., Foreman, O., Kirkpatrick, D. S., & Sheng, M. (2014) · Nature · doi:10.1038/nature13418 · Cited by 855 · cited 1×
“USP30 is a mitochondria-localised DUB. Inhibiting USP30 has recently been proposed by separate groups as an approach to treat Parkinson's disease [132] [133] [134] and cancer [135] .”
A dynamic role of HAUSP in the p53-Mdm2 pathway
Li, M., Brooks, C. L., Kon, N., & Gu, W. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00157-1 · Cited by 679 · cited 1×
“Inhibition of USP7 is expected to increase p53 levels, leading to anti-tumour activity [79,80].”
Chauhan, D., Tian, Z., Nicholson, B., Kumar, K. G. S., Zhou, B., Carrasco, R., McDermott, J. L., Leach, C. A., Fulcinniti, M., Kodrasov, M. P., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.007 · Cited by 589 · cited 1×
“) injection at 10 mg/kg twice weekly for 3 weeks to humanMM1S multiple myeloma tumour-bearing mice [88].”
Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme.
Reverdy, C., Conrath, S., Lopez, R., Planquette, C., Atmanene, C., Collura, V., Harpon, J., Battaglia, V., Vivat, V., Sippl, W., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.02.007 · Cited by 270 · cited 1×
“HBX19818 (24) was discovered by Hybrigenics from a high-throughput USP7/Ub-AMC screen [91,92].”
Selective dual inhibitors of the cancer-related deubiquitylating proteases USP7 and USP47.
Weinstock, J., Wu, J., Cao, P., Kingsbury, W. D., McDermott, J. L., Kodrasov, M. P., McKelvey, D. M., Suresh Kumar, K. G., Goldenberg, S. J., Mattern, M. R., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200276j · Cited by 187 · cited 1×
“Subsequent optimisation led to compound 22, which as well as being more potent for USP7 and USP47, is significantly less reactive with glutathione and more stable in plasma [86].”
Cited by
Deubiquitylating enzymes and drug discovery: emerging opportunities
Harrigan, J. A., Jacq, X., Martin, N. M., & Jackson, S. P. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.152 · Cited by 940
Ubiquitin–proteasome system (UPS) as a target for anticancer treatment
Park, J., Cho, J., & Song, E. J. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01281-8 · Cited by 408
Discovery and characterization of highly potent and selective allosteric USP7 inhibitors
Gavory, G., O'Dowd, C. R., Helm, M. D., Flasz, J., Arkoudis, E., Dossang, A., Hughes, C., Cassidy, E., McClelland, K., Odrzywol, E., et al. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2528 · Cited by 224
Bioactivity descriptors for uncharacterized chemical compounds
Bertoni, M., Duran-Frigola, M., Badia-i-Mompel, P., Pauls, E., Orozco-Ruiz, M., Guitart-Pla, O., Alcalde, V., Diaz, V. M., Berenguer-Llergo, A., Brun-Heath, I., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24150-4 · Cited by 92
Identification and structure-guided development of pyrimidinone based USP7 inhibitors
O’Dowd, C. R., Helm, M. D., Rountree, J. S. S., Flasz, J. T., Arkoudis, E., Miel, H., Hewitt, P. R., Jordan, L., Barker, O., Hughes, C., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00512 · Cited by 71
Metadata
- Authors
- Kemp, M.
- Venue
- Progress in Medicinal Chemistry
- Publisher
- Elsevier
- Published
- 2016
- Volume
- 55
- Pages
- 149-192
- ISSN
- 0079-6468 (ISSN-L)
- OpenAlex
- W2285013942
- Cited by
- 70
- References
- 8
- FWCI
- 10.33
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent Advances in the Discovery of Deubiquitinating Enzyme Inhibitors. https://app.cochat.ai/papers/10.1016/bs.pmch.2015.10.002
- The paper
- Kemp, M. (2016). Recent Advances in the Discovery of Deubiquitinating Enzyme Inhibitors. Progress in Medicinal Chemistry. https://doi.org/10.1016/bs.pmch.2015.10.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.